Press release
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024.\n\n“2025 is off to a tremendous start as we reported yet another quarter of record revenue,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “Beyond the continued execution of our foundational wave of growth in the commercial business, throughout the balance of the year we’ll progress our innovation and revolution waves of growth with the readout of TETON 2 in idiopathic pulmonary fibrosis and the planned commencement of our UKidney first in human clinical study, respectively. Moreover, we’re excited to advance our multiple shots on goal approach to creating an unlimited supply of transplantable organ alternatives with anticipated filings of investigational new drug applications with the FDA for our UHeart and UThymoKidney products.”\n\nMichael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, “This quarter’s record revenue performance reflects the diligent efforts and strategic focus of our commercial team as we continue to expand our reach and solidify our position in the pulmonary hypertension marketplace as the prostacyclin products of choice. We look forward to building on this performance for the remainder of the year.”\n\nFirst Quarter 2025 Financial Results\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n \n\n\n\nThree Months\nEnded\nMarch 31,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTotal revenues\n\n\n\n$\n\n\n\n794.4\n\n\n\n \n\n\n\n$\n\n\n\n677.7\n\n\n\n \n\n\n\n$\n\n\n\n116.7\n\n\n\n \n\n\n\n17\n\n\n\n%\n\n\n\n\n\nNet income\n\n\n\n$\n\n\n\n322.2\n\n\n\n \n\n\n\n$\n\n\n\n306.6\n\n\n\n \n\n\n\n$\n\n\n\n15.6\n\n\n\n \n\n\n\n5\n\n\n\n%\n\n\n\n\n\nNet income, per basic share\n\n\n\n$\n\n\n\n7.18\n\n\n\n \n\n\n\n$\n\n\n\n6.52\n\n\n\n \n\n\n\n$\n\n\n\n0.66\n\n\n\n ...